M STEPHANE GAY

Rhumatologue

📍 ST SATURNIN (72)SalariéRPPS 10000596352

✨ Profil synthétique

IA · 22/05/2026

Le Dr Stéphane Gay est un rhumatologue salarié à St Saturnin. Ses publications sur PubMed suggèrent une implication dans la recherche sur les aspects génétiques des maladies rhumatismales ainsi que sur les traitements par biothérapies, notamment les anti-TNF et les biothérapies non anti-TNF. Il contribue ainsi à l'avancement des connaissances dans le domaine de la rhumatologie.

Expertises présumées

Maladies rhumatismales
Thérapies anti-TNF
Biothérapies non anti-TNF
Génétique des maladies rhumatismales
Traitement de la polyarthrite rhumatoïde
Thérapies biologiques en rhumatologie
Rhumatisme auto-immun

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

SSR CENTRE DE L'ARCHE
1 BD DE MAULE, 72650 ST SATURNIN
☎ 0243517272Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial

Arthritis & rheumatology (Hoboken, N.J.) · 2020

📚 170 citations🎯 RCR 9.08Top 3% NIH🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

ObjectiveTo assess the risk of major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA) treated with tocilizumab compared to those treated with the tumor necrosis factor inhibitor etanercept.MethodsThis randomized, open‐label, parallel‐group trial enrolled patients with active seropositive RA (n = 3,080) who had an inadequate response to conventional synthetic disease‐modifying antirheumatic drugs and who had at least 1 cardiovascular (CV) risk factor. Patients were randomly assigned 1:1 to receive open‐label tocilizumab at 8 mg/kg/month or etanercept at 50 mg/week. All patients were followed up for a mean of 3.2 years. The primary end point was comparison of time to first occurrence of MACE. The trial was powered to exclude a relative hazard ratio for MACE of 1.8 or higher in the tocilizumab group compared to the etanercept group.ResultsBy week 4 of treatment, the serum low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, and triglyceride levels were a median 11.1%, 5.7%, and 13.6% higher, respectively, in patients receiving tocilizumab compared to those receiving etanercept (each P < 0.001). During follow‐up, 83 MACE occurred in the tocilizumab group compared to 78 MACE in the etanercept group. The estimated hazard ratio for occurrence of MACE in the tocilizumab group relative to the etanercept group was 1.05 (95% confidence interval 0.77–1.43). Results were similar in sensitivity analyses and in the on‐treatment population analysis. Adverse events occurred more frequently in the tocilizumab group, including serious infection and gastrointestinal perforation.ConclusionThe results of this trial, which provide insights into the CV safety of tocilizumab as compared to etanercept, ruled out a risk for occurrence of MACE of 1.43 or higher in patients treated with tocilizumab. This result should be interpreted in the context of the clinical efficacy and non‐CV safety of tocilizumab.

PU.1 controls fibroblast polarization and tissue fibrosis

Nature · 2019

📚 162 citations🎯 RCR 6.12Top 6% NIH🔓 Open Access📄 PDF gratuit ↗

Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis

Annals of the rheumatic diseases · 2014

📚 151 citations🎯 RCR 5.11Top 8% NIH🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

M STEPHANE GAY

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal47

Génétique2

Anti-TNF1

Biothérapies non-anti-TNF1

Partager cette fiche